FASN overexpression has been documented in a wide array of cancers, including breast cancer, prostate cancer, colorectal cancer, lung cancer, and ovarian cancer. The level of FASN expression often correlates with poor prognosis, increased tumor aggressiveness, and resistance to chemotherapy.
